Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models

BACKGROUND: Despite the poor prognosis of triple-negative breast cancer (TNBC) brain metastases, there are no approved systemic therapies. We explored the DNA-damaging poly(ADP-ribose) polymerase inhibitor (PARPi) niraparib in intracranial mouse models of breast cancer susceptibility protein (BRCA)-...

Descripción completa

Detalles Bibliográficos
Autores principales: Sambade, Maria J, Van Swearingen, Amanda E D, McClure, Marni B, Deal, Allison M, Santos, Charlene, Sun, Kaiming, Wang, Jing, Mikule, Keith, Anders, Carey K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212882/
https://www.ncbi.nlm.nih.gov/pubmed/32642648
http://dx.doi.org/10.1093/noajnl/vdz005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212882/
https://www.ncbi.nlm.nih.gov/pubmed/32642648
http://dx.doi.org/10.1093/noajnl/vdz005

Ejemplares similares